June 11, 2026 • 20 mins
A clean diagnosis feels like an X-ray: obvious problem, obvious fix. Alzheimer’s disease is the opposite, and the arrival of disease-modifying anti-amyloid therapies like lecanemab and donanemab makes that gap impossible to ignore. We dig into why real-world patients do not look like “pristine” clinical trial participants, and why a simple amyloid positive label can hide wildly different biology, risks, and likely outcomes.
We explore what happens when amyloid burden is patchy or borderline, how centiloid scores and CSF biomarkers (especially the amyloid beta 42 to 40 ratio) create a probabilistic gray zone, and why cognitive decline often reflects more than plaques alone. Cerebrovascular disease and white matter injury can team up with modest amyloid to push a brain over the edge, which changes what “treating the cause” even means.
Then we follow the fire inward to tau. Tau tangles disrupt neurons from the inside, and tau PET with Braak staging can reveal severe pathology even when someone still functions well, thanks to cognitive reserve. From there, we zoom out to the ATNIVS framework: Amyloid, Tau, Neurodegeneration, Inflammation, Vascular pathology, and Synuclein. We connect blood biomarkers like plasma NFL and GFAP to active neurodegeneration and neuroinflammation, and we explain why ARIA (amyloid-related imaging abnormalities) risk rises when fragile vessels, inflammation, and cerebral amyloid angiopathy collide with plaque-clearing antibodies.
Finally, we cover a provocative twist: seed amplification assays detecting hidden alpha-synuclein in a meaningful share of patients diagnosed with Alzheimer’s, pointing to copathology that can change prognosis and potentially mask drug benefit. If you care about Alzheimer’s biomarkers, precision neurology, and the future of combination therapies, listen through to the end, then subscribe, share the episode, and leave a review with your biggest takeaway.
This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.
Never miss an episode—subscribe on your favorite podcast app!
Listen
Watch
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
SPEAKER_01 (00:00):
Usually um when you think about a medical diagnosis,
there's this expectation of youknow mechanical precision.
SPEAKER_00 (00:05):
Aaron Powell Right, like a clear-cut answer.
SPEAKER_01 (00:07):
Exactly.
You break your arm, the x-rayshows that jagged white line,
and the doctor just points toit.
It's either broken or notbroken.
You put a caft on it, and you gohome.
SPEAKER_00 (00:15):
Yeah, it's a wonderfully binary system.
The biology in that case isincredibly straightforward.
SPEAKER_01 (00:20):
Aaron Powell But if we venture into the world of
neurodegeneration, sospecifically cognitive decline
and Alzheimer's disease, thatx-ray machine is well, it's
utterly useless.
SPEAKER_00 (00:32):
Right.
SPEAKER_01 (00:32):
We are looking at a diagnostic landscape that is
astonishingly murky.
SPEAKER_00 (00:36):
Aaron Powell It really is.
And things are getting even morecomplicated because of a massive
shift happening in medicineright now.
SPEAKER_01 (00:42):
Aaron Ross Powell Right, the new treatments.
SPEAKER_00 (00:43):
Exactly.
We are seeing a wave of newdisease-modifying therapies.
So drugs like Lacanimab andDoninamab, they're making their
way out of clinical trials andinto everyday medical practice.
And I mean, the transition froma highly controlled trial to a
real-world clinic is a profoundshock to the system.
SPEAKER_01 (01:00):
Aaron Powell, which is exactly what we're exploring
for you today on this deep dive.
We're looking at a pivotaleditorial from the Journal of
Prevention of Alzheimer'sdisease.
This was published in May 2026by Dr.
Michael S.
Rafi.
SPEAKER_00 (01:13):
Yeah, it's a fantastic piece of writing.
SPEAKER_01 (01:15):
It really is.
He details how these new drugsare basically colliding with the
messy, complicated reality ofhuman biology.
SPEAKER_00 (01:23):
Because in a clinical trial, you select
pristine patients who fit verynarrow specific criteria.
SPEAKER_01 (01:29):
Right.
They have to check all theboxes.
SPEAKER_00 (01:30):
Exactly.
But in the real world, patientsdo not fit into neat little
boxes.
The editorial argues that thetraditional black and white way
we diagnose Alzheimer's iscompletely obsolete.
SPEAKER_01 (01:40):
So we're moving past it.
SPEAKER_00 (01:42):
We have to.
We are moving toward a frameworkcalled ATNIVS, which looks at a
patient's complete biologicalfingerprint.
SPEAKER_01 (01:48):
Okay, let's unpack this because to appreciate this
new framework, we really need tounderstand the old rules.
SPEAKER_00 (01:54):
The binary rule.
SPEAKER_01 (01:55):
Right.
During the clinical trials forthose new anti-amyloid drugs,
eligibility was strictly binary.
You either had amyloid plaquesin your brain, meaning you were
amyloid positive, or you didn't.
SPEAKER_00 (02:06):
Just a simple yes or no.
SPEAKER_01 (02:07):
Yeah, I like to think of it like a strict
bouncer at a VIP club.
You walk up, the bouncer checksyour brain for amyloid, and you
either have the risk can and getthe treatment, or you're turned
away.
SPEAKER_00 (02:18):
And you know, regulatory agencies and
insurance pairs strongly preferthat binary system because it is
easy to manage.
SPEAKER_01 (02:24):
It makes the paperwork simple.
SPEAKER_00 (02:25):
Right.
But the editorial highlights afascinating real-world study by
Kurihara and colleagues thatdismantles that bouncer analogy
completely.
SPEAKER_01 (02:34):
Oh, really?
SPEAKER_00 (02:35):
Yeah.
They found that among patientstreated in everyday practice,
getting that amyloid wristbanddoes not mean you have the same
disease as everyone else in theclub.
SPEAKER_01 (02:45):
Wait, if they all have amyloid plaques, how are
their diseases different?
SPEAKER_00 (02:48):
Well, the study revealed massive biological
variation.
To start, 21% of the treatedindividuals only had regional
amyloid positivity.
SPEAKER_01 (02:57):
Regional.
You mean like it's only isolatedto certain neighborhoods of the
brain rather than spreadeverywhere?
SPEAKER_00 (03:03):
Exactly.
In classic symptomaticAlzheimer's disease, the amyloid
plaques typically form a diffuseblanket over the entire outer
layer of the brain, the cortex.
SPEAKER_01 (03:13):
Right.
It's everywhere.
SPEAKER_00 (03:14):
But in this 21% subgroup, the amyloid was patchy
and localized.
The researchers measured thisusing something called centeloid
burden, which uh calculates thesheer density or weight of the
plaques.
SPEAKER_01 (03:26):
Okay.
SPEAKER_00 (03:26):
And this group had a remarkably low centeloid score.
SPEAKER_01 (03:29):
Aaron Powell So instead of a massive blizzard
covering the whole landscape,they just have like a light
dusting of snow and a fewscattered areas.
SPEAKER_00 (03:37):
That is a perfect visual.
And clinically, this subgrouplooked different too.
They tended to be older and theywere in much milder stages of
cognitive decline.
SPEAKER_01 (03:44):
Wait, hold on.
If they only have a lightdusting of localized amyloid,
why are they in a clinic gettinga heavy-duty drug like
Lacanimab?
I mean, why are they showingcognitive impairment at all?
SPEAKER_00 (03:55):
Aaron Powell That puzzle goes to the heart of the
editorial.
It proves that while amyloid isa driver of the disease, it is
not the sole cause of thepatient's symptoms.
Okay.
If someone has a failing memorybut only a tiny bit of amyloid,
a copilot must be driving thedamage.
In this subgroup, theresearchers found that copilot,
it's cerebrovascular disease.
SPEAKER_01 (04:15):
Aaron Powell Cerebrovascular disease.
So um issues with the bloodvessels inside the brain.
SPEAKER_00 (04:21):
Aaron Powell Yes.
They quantified this usingphysicus scores, which is a
visual scale applied to MRIscans.
It measures white matterlesions.
SPEAKER_01 (04:29):
Aaron Ross Powell Which are what exactly?
SPEAKER_00 (04:31):
Essentially, it shows areas where the
microscopic blood vessels in thebrain have thickened or become
blocked over time.
It is essentially the visibleaftermath of thousands of
microscopic mini strokes.
SPEAKER_01 (04:43):
Oh wow.
Thousands of them.
SPEAKER_00 (04:44):
Yeah.
The blood flow is restricted, sothe brain tissue in those areas
is slowly starved of oxygen.
SPEAKER_01 (04:49):
Aaron Powell Oh, wow.
So you have this one-two punch.
The amyloid isn't enough tocause the symptoms on its own,
but when you combine it with thepoor blood flow and vascular
damage, the brain's networkstarts to collapse.
SPEAKER_00 (05:02):
Aaron Powell It's like a bridge.
SPEAKER_01 (05:04):
If the bridge has a little bit of rust, the amyloid,
it can still hold traffic.
Yeah.
But if it has rust and it getshit by an earthquake, the
vascular disease, the wholething comes down.
SPEAKER_00 (05:12):
Aaron Powell That analogy perfectly captures the
mechanical synergy happening inthe brain.
The rust weakens the structureand the earthquake breaks it.
And this highlights the dangerof treating amyloid as a binary
yes or no.
If you give a patient a powerfuldrug to remove a tiny bit of
rust, but the primary cause oftheir cognitive decline is
(05:32):
ongoing earthquake damage,you're not actually altering the
course of their disease.
SPEAKER_01 (05:36):
Aaron Powell So if a light dusting is enough to cause
symptoms when there's vasculardamage, uh, what happens when
someone barely has any amyloidat all?
How are we even drawing the linebetween amyloid positive and
amyloid negative?
SPEAKER_00 (05:49):
Aaron Powell Right, that's where it gets tricky.
The researchers draw that lineby analyzing the cerebrospinal
fluid, or CSF, that's the liquidthat bathes the brain and spinal
cord.
Specifically, they look at theratio of two proteins, a beta 42
to a beta 40.
SPEAKER_01 (06:03):
Why compare those two specific proteins?
And what does a ratio actuallytell us about the brain?
SPEAKER_00 (06:07):
Aaron Powell Well, what's fascinating here is that
it's an incredibly cleverdiagnostic tool based on how
these proteins behave.
Your brain constantly producesboth of them.
A beta 40 is relatively shortand floats around harmlessly.
It is soluble.
SPEAKER_01 (06:19):
Okay, so it just washes away.
SPEAKER_00 (06:20):
Exactly.
But a beta 42 is slightlylonger, and crucially, it is
extremely sticky.
SPEAKER_01 (06:26):
Aaron Powell So the 42 is the one that clumps
together to form the plaques.
SPEAKER_00 (06:29):
Yes.
When a beta 42 starts clumpingtogether to form solid plaques
in the brain, it gets trappedthere.
It stops flowing down into thespinal fluid.
Oh I see.
So if a doctor does a lumbarpuncture and sees a severe drop
in a beta 42 compared to theharmless a beta 40, they know
the sticky protein is currentlyaccumulating inside the
patient's brain.
SPEAKER_01 (06:49):
Aaron Powell That is brilliant.
Yep.
You aren't just looking for thepresence of the bad protein,
you're looking for its absencein the fluid because it's stuck
upstream.
SPEAKER_00 (06:57):
Exactly.
SPEAKER_01 (06:58):
But I imagine that drop in the ratio doesn't happen
overnight.
SPEAKER_00 (07:01):
No, it happens very gradually.
And the study found that eventhough all the treated patients
were technically stamped asamyloid positive to qualify for
the drug, a subset of themhovered right on the edge of the
cutoff.
SPEAKER_01 (07:13):
Oh really?
SPEAKER_00 (07:14):
Yeah.
They fell into a murky, likelypositive range.
SPEAKER_01 (07:17):
Aaron Powell So they basically barely crossed the
finish line.
SPEAKER_00 (07:20):
Aaron Powell Which reveals a fundamental truth
here.
Biomarker thresholds areprobabilistic, not absolute.
Biology is a dial, it's not alight switch.
SPEAKER_01 (07:29):
That makes sense.
SPEAKER_00 (07:30):
The medical system wants a clear cutoff to
determine who gets aprescription.
But a patient hovering near thatcut point is in a transitional
biological state.
SPEAKER_01 (07:39):
Aaron Powell Meaning they might just be at the very,
very beginning of their amyloidaccumulation.
SPEAKER_00 (07:43):
Aaron Powell Or they might have mixed etiologies,
meaning they have a negligibleamount of amyloid, and their
memory loss is actually beingcaused by something else
entirely.
Wow.
The editorial stress is thatthis raises a massive unknown.
We are treating a biologicalgray area with a black and white
therapeutic protocol, and wehonestly do not know how
effective or how safe theseanti-amyloid therapies will be
(08:07):
for borderline patients.
SPEAKER_01 (08:08):
Here's where it gets really interesting for me.
If the amyloid line is soblurry, and amyloid itself isn't
necessarily the direct immediatekiller of the brain cells, what
is?
Like if amyloid is the matchthat starts the fire, what is
the actual fire?
SPEAKER_00 (08:22):
Aaron Ross Powell The Fire is a protein called
Tau.
Amyloid plaques build up slowlyoutside the brain cells, setting
a toxic stage.
But tau proteins operate insidethe neurons.
SPEAKER_01 (08:32):
Inside the cell.
So how does tau actually destroythe cell?
SPEAKER_00 (08:34):
Well, inside every neuron, there's a transport
system that looks like tinytrain tracks carrying nutrients
from the center of the cell downto the synapses.
SPEAKER_01 (08:42):
Okay, I'm picturing it.
SPEAKER_00 (08:43):
In a healthy brain, tau acts like the wooden
railroad ties, holding thetracks straight and stable.
But in Alzheimer's, the tauproteins become deformed.
They detach from the tracks andtangle together into clumps.
SPEAKER_01 (08:55):
So the railroad ties just rot away.
SPEAKER_00 (08:57):
The ties dissolve, the tracks collapse, and the
neuron literally starves todeath from the inside out.
SPEAKER_01 (09:03):
That sounds brutal.
SPEAKER_00 (09:04):
It is.
This tau pathology remains theabsolute strongest biological
correlate of clinicalimpairment.
Where the tau goes, brain celldeath follows.
SPEAKER_01 (09:13):
Aaron Powell And to measure this, the study used a
highly advanced PE tracer calleduh 18F MK6240, and they found a
wild variance in the tau burdenamong these real-world patients
getting licanomap.
SPEAKER_00 (09:25):
The variance was staggering.
They measured the spread of thefire using break stages.
SPEAKER_01 (09:29):
Aaron Powell Break stages.
SPEAKER_00 (09:30):
Yeah.
Break stage zero means virtuallyno tau tangles, while stage six
means the tangles have spreadout of the memory centers and
swept across the entire brain,causing massive widespread
destruction.
SPEAKER_01 (09:44):
Aaron Powell What totally blew my mind in the
editorial was the disconnectbetween those stages and the
patient's actual symptoms.
SPEAKER_00 (09:51):
Right.
The clinical presentation.
SPEAKER_01 (09:52):
Yeah.
You had patients who performedidentically on memory tests in
the clinic.
I mean, they were at the exactsame clinical stage of cognitive
decline, but their brains lookedcompletely different on the PET
scans.
SPEAKER_00 (10:03):
Aaron Powell It's incredible.
You can have someone withminimal Tao burden who shows
undeniable severe cognitiveimpairment.
Yeah.
On the flip side, you havepatients with highly advanced
tau pathology, break stage fiveor six, who are still
functioning quite well,categorized only with mild
cognitive impairment.
SPEAKER_01 (10:20):
That's wild.
SPEAKER_00 (10:21):
They have a raging fire in their brain, yet they
are still holding a conversationand paying their bills.
SPEAKER_01 (10:25):
How is that even possible?
If the tau is actively starvingthe cells to death, how can
someone with a massive fire bedoing fine while someone with a
tiny spark is losing theirmemory?
SPEAKER_00 (10:36):
It comes down to a concept called cognitive
reserve.
It's basically the brain'smechanical resilience.
Okay.
Some brains develop incrediblydense, redundant neural networks
over a lifetime.
If a tau tangle destroys onepathway, a highly resilient
brain will just route theelectrical signal around the
damage, like a GPS finding adetour when a highway is
(10:58):
blocked.
SPEAKER_01 (10:59):
So the person with high tau just have more detours
built into their brain.
SPEAKER_00 (11:02):
Exactly.
They can sustain massivestructural damage before the
clinical symptoms appear simplybecause their brain keeps
improvising workarounds.
SPEAKER_01 (11:09):
That's amazing.
SPEAKER_00 (11:10):
And the person with low tau but severe symptoms
likely lacks those redundantpathways, or they have other
copathologies like the vascularearthquake damage we talked
about that have alreadydestroyed their detours.
SPEAKER_01 (11:22):
Aaron Powell So how does knowing a patient's tau
level change the decision toprescribe an amyloid drug if
you're just clearing out theamyloid plaques?
Why does the internal tau firematter?
SPEAKER_00 (11:33):
It matters heavily for setting realistic
expectations for the patient'sfuture.
How so?
If a patient comes in withextremely high tau levels, break
stage five or six, the cellularfire is already raging out of
control.
Removing the amyloid matches atthat late stage might not slow
down the clinical decline in ameaningful way.
SPEAKER_01 (11:51):
Ah, I see.
SPEAKER_00 (11:52):
The runaway train has already left the station.
SPEAKER_01 (11:54):
The structural damage is already done.
SPEAKER_00 (11:56):
Exactly.
But if patient has a very lowtau, they might be the ideal
candidate.
You remove the amyloid matchesbefore the widespread internal
fire ever really ignites,potentially offering genuine
long-term disease modification.
SPEAKER_01 (12:10):
Aaron Powell That reframes the entire
conversation.
You aren't just telling apatient, you know, take this
drug and you'll get better.
You're assessing their specificcellular fire to see if a
specific hose will actually putit out.
SPEAKER_00 (12:20):
Aaron Powell Which brings us to the broader ATNIVS
framework, the editorialchampions.
We've covered the A for amyloidand the T for tau.
Right.
But the framework demands welook at the hidden amplifiers of
the disease.
Neurodegeneration, which is theN inflammation, the I, vascular
pathology, the V, and alphasynucline, the S.
SPEAKER_01 (12:40):
Okay, let's look at those hidden amplifiers.
How are we measuring the N, theneurodegeneration?
SPEAKER_00 (12:46):
The study utilized plasma markers, basically
advanced blood tests.
For neurodegeneration, theymeasured plasma NFL or
neurofilament light chain.
SPEAKER_01 (12:55):
What are neurofilaments?
SPEAKER_00 (12:56):
They're the structural scaffolding proteins
that give a neuron its physicalshape.
When a brain cell finally diesand bursts open, that
scaffolding shatters and spillsout into the surrounding fluid,
eventually making its way intothe bloodstream.
So measuring high levels of NFLin the blood gives you a
real-time metric of active,ongoing brain cell death.
(13:17):
It's like seeing structuraldebris floating in the water
after a shipwreck.
SPEAKER_01 (13:21):
That is a dark image, but it makes perfect
sense.
And what about the eye forinflammation?
SPEAKER_00 (13:26):
For inflammation, they measured GFE, a protein
released by astrocytes.
Astrocytes are essentially themaintenance and immune crew of
the brain.
SPEAKER_01 (13:34):
The cleanup crew.
SPEAKER_00 (13:35):
Yeah.
When they detect damage likeamyloid plaques or dying cells,
they activate and try to clearthe debris.
But in neurodegenerativedisease, they often become
hyperactive, leading to chronic,toxic brain inflammation.
High GFA means the brain'simmune system is stuck in
overdrive.
SPEAKER_01 (13:52):
And we already covered the V, the vascular
pathology causing thosemicroscopic blood vessel
blockages.
So why are these three, thedying cells, the chronic
inflammation, and the vasculardamage, so critical when a
doctor is considering ananti-amyloid therapy?
SPEAKER_00 (14:06):
The most urgent reason is safety, specifically
the risk of a severe side effectcalled ARIA.
SPEAKER_01 (14:12):
ARI, amyloid-related imaging abnormalities.
This is the major safety warningon drugs like lacanimab,
involving brain swelling andmicrohemorrhages.
SPEAKER_00 (14:21):
Right.
To understand why ARIA happens,you have to look at how the drug
works mechanically.
These drugs are monoclonalantibodies designed to
forcefully strip amyloid out ofthe brain.
Okay.
But amyloid doesn't just sit inisolated plaques, it also embeds
itself deeply into the walls ofthe brain's blood vessels, a
condition called cerebralamyloid angiopathy.
SPEAKER_01 (14:39):
So the drug is literally attacking the amyloid
inside the blood vessel walls.
SPEAKER_00 (14:44):
Yes.
It triggers the brain's immunecells to attack and clear that
embedded amyloid.
If you do this in a patientwhose blood vessels are already
fragile and thickened fromvascular disease and surrounded
by hyperactive angry astrocytescausing inflammation, the
cleanup process is incrediblydestructive.
SPEAKER_01 (15:01):
That sounds dangerous.
SPEAKER_00 (15:02):
It is.
As the amyloid is stripped away,the compromised vessel walls
become porous, they leak fluid,causing brain swelling, or they
rupture entirely, causingbleeding.
SPEAKER_01 (15:12):
So if a doctor only looks at the binary amyloid
wristband and ignores theinflammation and vascular
damage, they might prescribe adrug to a patient whose blood
vessels literally cannot survivethe structural stress of the
cleanup.
SPEAKER_00 (15:25):
Exactly.
It's a profound safety risk thatis completely invisible if you
only focus on the amyloid.
SPEAKER_01 (15:30):
That is terrifying.
But there's one more letter inthis framework that caught me
completely off guard.
SPEAKER_00 (15:35):
The S.
SPEAKER_01 (15:36):
The S at the very end.
Alpha Sinucline.
SPEAKER_00 (15:39):
That finding is arguably the most provocative
paradigm shift in the entireeditorial.
SPEAKER_01 (15:44):
Because alpha synucline is a totally different
protein.
It's a one that misfolds andclumps together to form Lewy
bodies, which are the hallmarkof Parkinson's disease and Lewy
body dementia.
It has completely differentmechanisms than amyloid or tau.
SPEAKER_00 (15:58):
It does.
It attacks different regions ofthe brain and causes a very
different cascade of cellularfailure.
SPEAKER_01 (16:03):
Yet the study ran tests on these real-world
patients, people diagnosed withAlzheimer's disease who are
receiving an Alzheimer's drug,and found that roughly 25% of
them tested positive foralpha-sinuclein in their spinal
fluid.
A quarter of the patients.
SPEAKER_00 (16:16):
And many of them showed minimal, if any, clinical
signs of Lewy body disease.
Clinically, they just look likethey had Alzheimer's.
SPEAKER_01 (16:24):
How do the researchers even find it if
there were no symptoms?
SPEAKER_00 (16:27):
They used a revolutionary new tool called a
seed amplification assay, orSAA.
SPEAKER_01 (16:32):
How does an SAA actually work?
Like how do you find amicroscopic trace of a different
disease hidden in the spinalfluid?
SPEAKER_00 (16:39):
It's an ingenious piece of molecular engineering.
Alpha synucleane causes damageby misfolding and then
corrupting the healthy proteinsaround it, forcing them to
misfold too.
SPEAKER_01 (16:49):
Like a domino effect.
SPEAKER_00 (16:50):
Right.
The SAA exploits this behavior.
Researchers take a tiny sampleof the patient's spinal fluid
and place it in a tube filledwith perfectly healthy synthetic
alpha cytocline.
SPEAKER_01 (17:02):
So they mix the patient's fluid with normal
proteins.
SPEAKER_00 (17:04):
Then they shake it.
If the patient has even amicroscopic trace of the
misfolded seed in their fluid,it will start corrupting the
healthy synthetic proteins inthe tube, triggering a rapid
chain reaction.
SPEAKER_01 (17:16):
It's like dropping a single zombie into a crowded
room to see if an outbreakstarts.
SPEAKER_00 (17:21):
That is exactly the mechanism.
Within hours, the misfoldedproteins multiply until the
machine can easily detect them.
Wow.
And using this tool, wediscovered that 25% of these
Alzheimer's patients areactively harboring a second,
completely distinctneurodegenerative disease.
SPEAKER_01 (17:37):
So a quarter of these people have two separate
brain-destroying fires burningat the same time.
SPEAKER_00 (17:41):
If we connect this to the bigger picture, we call
it coproteinopathy.
The biology does not care aboutour neat diagnostic boxes.
SPEAKER_01 (17:48):
Obviously not.
SPEAKER_00 (17:49):
And having senuclein copathology drastically alters a
patient's prognosis.
The two diseases interact,accelerating the overall
cognitive decline.
And crucially, we currently havevery little data on how a brain
dealing with hidden alphasnuclein responds to an
anti-amyloid therapy.
SPEAKER_01 (18:07):
Because if you have a whole second army of proteins
destroying your neurons, justputting away the amyloid matches
might not even slow the declinedown.
SPEAKER_00 (18:14):
Right.
The clinical benefit might beentirely masked by the
progression of the hidden Lewybody pathology.
SPEAKER_01 (18:20):
So what does this all mean?
Zooming out from all thespecific proteins and
mechanisms, the core takeawayfor you listening is this
Alzheimer's disease is not asingle monolith.
SPEAKER_00 (18:30):
No, it's an umbrella term for a highly individualized
biological event.
SPEAKER_01 (18:34):
Anti-amyloid therapies are remarkable
breakthroughs, but they do notoperate in a vacuum.
The effects of removing amyloidunfold against an incredibly
complex backdrop of internal taufires, dying structural
scaffolding, vascular rust,brain inflammation, and
completely hiddenco-conspirators like
alpha-sinucline.
SPEAKER_00 (18:52):
The ATNIVS profile provides the multidimensional
map required for true precisionmedicine.
It allows a physician to look attwo patients who both have early
Alzheimer's and understand whythey have entirely different
trajectories, entirely differentside effect risks, and require
completely different care plans.
SPEAKER_01 (19:10):
We started this conversation talking about the
comforting simplicity of anx-ray, a clean binary problem
with a clean binary fix.
But the human brain is more likea massive, intricate orchestra.
SPEAKER_00 (19:23):
A very fragile orchestra.
SPEAKER_01 (19:24):
And if 25% of these patients have hidden alpha
synucline and others have heavyvascular damage or raging towel
fires, it means the stringsection is out of tune, the
brass is playing the wrong song,and the percussion is completely
missing.
Clearing out the amyloid is likefixing a single broken violin
string.
It's a start.
But you can't fix one string andexpect the symphony to sound
(19:46):
perfect.
It leaves you wondering ifyou're putting out one fire in a
burning house, what does thefuture of combination therapies
really look like?
SPEAKER_00 (19:54):
That's the only way forward.
SPEAKER_01 (19:55):
Imagine a bespoke personalized cocktail of
therapies tailored to targetyour exact biological signature.
We have to trade the comfort ofthe simple X ray for the power
of a multi dimensional map.
And while those diagnosticwaters might look murky right
now, mapping out every singleinstrument in that orchestra is
exactly what will help usfinally navigate them.
Usually um when you think about a medical diagnosis,
there's this expectation of youknow mechanical precision.
SPEAKER_00 (00:05):
Aaron Powell Right, like a clear-cut answer.
SPEAKER_01 (00:07):
Exactly.
You break your arm, the x-rayshows that jagged white line,
and the doctor just points toit.
It's either broken or notbroken.
You put a caft on it, and you gohome.
SPEAKER_00 (00:15):
Yeah, it's a wonderfully binary system.
The biology in that case isincredibly straightforward.
SPEAKER_01 (00:20):
Aaron Powell But if we venture into the world of
neurodegeneration, sospecifically cognitive decline
and Alzheimer's disease, thatx-ray machine is well, it's
utterly useless.
SPEAKER_00 (00:32):
Right.
SPEAKER_01 (00:32):
We are looking at a diagnostic landscape that is
astonishingly murky.
SPEAKER_00 (00:36):
Aaron Powell It really is.
And things are getting even morecomplicated because of a massive
shift happening in medicineright now.
SPEAKER_01 (00:42):
Aaron Ross Powell Right, the new treatments.
SPEAKER_00 (00:43):
Exactly.
We are seeing a wave of newdisease-modifying therapies.
So drugs like Lacanimab andDoninamab, they're making their
way out of clinical trials andinto everyday medical practice.
And I mean, the transition froma highly controlled trial to a
real-world clinic is a profoundshock to the system.
SPEAKER_01 (01:00):
Aaron Powell, which is exactly what we're exploring
for you today on this deep dive.
We're looking at a pivotaleditorial from the Journal of
Prevention of Alzheimer'sdisease.
This was published in May 2026by Dr.
Michael S.
Rafi.
SPEAKER_00 (01:13):
Yeah, it's a fantastic piece of writing.
SPEAKER_01 (01:15):
It really is.
He details how these new drugsare basically colliding with the
messy, complicated reality ofhuman biology.
SPEAKER_00 (01:23):
Because in a clinical trial, you select
pristine patients who fit verynarrow specific criteria.
SPEAKER_01 (01:29):
Right.
They have to check all theboxes.
SPEAKER_00 (01:30):
Exactly.
But in the real world, patientsdo not fit into neat little
boxes.
The editorial argues that thetraditional black and white way
we diagnose Alzheimer's iscompletely obsolete.
SPEAKER_01 (01:40):
So we're moving past it.
SPEAKER_00 (01:42):
We have to.
We are moving toward a frameworkcalled ATNIVS, which looks at a
patient's complete biologicalfingerprint.
SPEAKER_01 (01:48):
Okay, let's unpack this because to appreciate this
new framework, we really need tounderstand the old rules.
SPEAKER_00 (01:54):
The binary rule.
SPEAKER_01 (01:55):
Right.
During the clinical trials forthose new anti-amyloid drugs,
eligibility was strictly binary.
You either had amyloid plaquesin your brain, meaning you were
amyloid positive, or you didn't.
SPEAKER_00 (02:06):
Just a simple yes or no.
SPEAKER_01 (02:07):
Yeah, I like to think of it like a strict
bouncer at a VIP club.
You walk up, the bouncer checksyour brain for amyloid, and you
either have the risk can and getthe treatment, or you're turned
away.
SPEAKER_00 (02:18):
And you know, regulatory agencies and
insurance pairs strongly preferthat binary system because it is
easy to manage.
SPEAKER_01 (02:24):
It makes the paperwork simple.
SPEAKER_00 (02:25):
Right.
But the editorial highlights afascinating real-world study by
Kurihara and colleagues thatdismantles that bouncer analogy
completely.
SPEAKER_01 (02:34):
Oh, really?
SPEAKER_00 (02:35):
Yeah.
They found that among patientstreated in everyday practice,
getting that amyloid wristbanddoes not mean you have the same
disease as everyone else in theclub.
SPEAKER_01 (02:45):
Wait, if they all have amyloid plaques, how are
their diseases different?
SPEAKER_00 (02:48):
Well, the study revealed massive biological
variation.
To start, 21% of the treatedindividuals only had regional
amyloid positivity.
SPEAKER_01 (02:57):
Regional.
You mean like it's only isolatedto certain neighborhoods of the
brain rather than spreadeverywhere?
SPEAKER_00 (03:03):
Exactly.
In classic symptomaticAlzheimer's disease, the amyloid
plaques typically form a diffuseblanket over the entire outer
layer of the brain, the cortex.
SPEAKER_01 (03:13):
Right.
It's everywhere.
SPEAKER_00 (03:14):
But in this 21% subgroup, the amyloid was patchy
and localized.
The researchers measured thisusing something called centeloid
burden, which uh calculates thesheer density or weight of the
plaques.
SPEAKER_01 (03:26):
Okay.
SPEAKER_00 (03:26):
And this group had a remarkably low centeloid score.
SPEAKER_01 (03:29):
Aaron Powell So instead of a massive blizzard
covering the whole landscape,they just have like a light
dusting of snow and a fewscattered areas.
SPEAKER_00 (03:37):
That is a perfect visual.
And clinically, this subgrouplooked different too.
They tended to be older and theywere in much milder stages of
cognitive decline.
SPEAKER_01 (03:44):
Wait, hold on.
If they only have a lightdusting of localized amyloid,
why are they in a clinic gettinga heavy-duty drug like
Lacanimab?
I mean, why are they showingcognitive impairment at all?
SPEAKER_00 (03:55):
Aaron Powell That puzzle goes to the heart of the
editorial.
It proves that while amyloid isa driver of the disease, it is
not the sole cause of thepatient's symptoms.
Okay.
If someone has a failing memorybut only a tiny bit of amyloid,
a copilot must be driving thedamage.
In this subgroup, theresearchers found that copilot,
it's cerebrovascular disease.
SPEAKER_01 (04:15):
Aaron Powell Cerebrovascular disease.
So um issues with the bloodvessels inside the brain.
SPEAKER_00 (04:21):
Aaron Powell Yes.
They quantified this usingphysicus scores, which is a
visual scale applied to MRIscans.
It measures white matterlesions.
SPEAKER_01 (04:29):
Aaron Ross Powell Which are what exactly?
SPEAKER_00 (04:31):
Essentially, it shows areas where the
microscopic blood vessels in thebrain have thickened or become
blocked over time.
It is essentially the visibleaftermath of thousands of
microscopic mini strokes.
SPEAKER_01 (04:43):
Oh wow.
Thousands of them.
SPEAKER_00 (04:44):
Yeah.
The blood flow is restricted, sothe brain tissue in those areas
is slowly starved of oxygen.
SPEAKER_01 (04:49):
Aaron Powell Oh, wow.
So you have this one-two punch.
The amyloid isn't enough tocause the symptoms on its own,
but when you combine it with thepoor blood flow and vascular
damage, the brain's networkstarts to collapse.
SPEAKER_00 (05:02):
Aaron Powell It's like a bridge.
SPEAKER_01 (05:04):
If the bridge has a little bit of rust, the amyloid,
it can still hold traffic.
Yeah.
But if it has rust and it getshit by an earthquake, the
vascular disease, the wholething comes down.
SPEAKER_00 (05:12):
Aaron Powell That analogy perfectly captures the
mechanical synergy happening inthe brain.
The rust weakens the structureand the earthquake breaks it.
And this highlights the dangerof treating amyloid as a binary
yes or no.
If you give a patient a powerfuldrug to remove a tiny bit of
rust, but the primary cause oftheir cognitive decline is
(05:32):
ongoing earthquake damage,you're not actually altering the
course of their disease.
SPEAKER_01 (05:36):
Aaron Powell So if a light dusting is enough to cause
symptoms when there's vasculardamage, uh, what happens when
someone barely has any amyloidat all?
How are we even drawing the linebetween amyloid positive and
amyloid negative?
SPEAKER_00 (05:49):
Aaron Powell Right, that's where it gets tricky.
The researchers draw that lineby analyzing the cerebrospinal
fluid, or CSF, that's the liquidthat bathes the brain and spinal
cord.
Specifically, they look at theratio of two proteins, a beta 42
to a beta 40.
SPEAKER_01 (06:03):
Why compare those two specific proteins?
And what does a ratio actuallytell us about the brain?
SPEAKER_00 (06:07):
Aaron Powell Well, what's fascinating here is that
it's an incredibly cleverdiagnostic tool based on how
these proteins behave.
Your brain constantly producesboth of them.
A beta 40 is relatively shortand floats around harmlessly.
It is soluble.
SPEAKER_01 (06:19):
Okay, so it just washes away.
SPEAKER_00 (06:20):
Exactly.
But a beta 42 is slightlylonger, and crucially, it is
extremely sticky.
SPEAKER_01 (06:26):
Aaron Powell So the 42 is the one that clumps
together to form the plaques.
SPEAKER_00 (06:29):
Yes.
When a beta 42 starts clumpingtogether to form solid plaques
in the brain, it gets trappedthere.
It stops flowing down into thespinal fluid.
Oh I see.
So if a doctor does a lumbarpuncture and sees a severe drop
in a beta 42 compared to theharmless a beta 40, they know
the sticky protein is currentlyaccumulating inside the
patient's brain.
SPEAKER_01 (06:49):
Aaron Powell That is brilliant.
Yep.
You aren't just looking for thepresence of the bad protein,
you're looking for its absencein the fluid because it's stuck
upstream.
SPEAKER_00 (06:57):
Exactly.
SPEAKER_01 (06:58):
But I imagine that drop in the ratio doesn't happen
overnight.
SPEAKER_00 (07:01):
No, it happens very gradually.
And the study found that eventhough all the treated patients
were technically stamped asamyloid positive to qualify for
the drug, a subset of themhovered right on the edge of the
cutoff.
SPEAKER_01 (07:13):
Oh really?
SPEAKER_00 (07:14):
Yeah.
They fell into a murky, likelypositive range.
SPEAKER_01 (07:17):
Aaron Powell So they basically barely crossed the
finish line.
SPEAKER_00 (07:20):
Aaron Powell Which reveals a fundamental truth
here.
Biomarker thresholds areprobabilistic, not absolute.
Biology is a dial, it's not alight switch.
SPEAKER_01 (07:29):
That makes sense.
SPEAKER_00 (07:30):
The medical system wants a clear cutoff to
determine who gets aprescription.
But a patient hovering near thatcut point is in a transitional
biological state.
SPEAKER_01 (07:39):
Aaron Powell Meaning they might just be at the very,
very beginning of their amyloidaccumulation.
SPEAKER_00 (07:43):
Aaron Powell Or they might have mixed etiologies,
meaning they have a negligibleamount of amyloid, and their
memory loss is actually beingcaused by something else
entirely.
Wow.
The editorial stress is thatthis raises a massive unknown.
We are treating a biologicalgray area with a black and white
therapeutic protocol, and wehonestly do not know how
effective or how safe theseanti-amyloid therapies will be
(08:07):
for borderline patients.
SPEAKER_01 (08:08):
Here's where it gets really interesting for me.
If the amyloid line is soblurry, and amyloid itself isn't
necessarily the direct immediatekiller of the brain cells, what
is?
Like if amyloid is the matchthat starts the fire, what is
the actual fire?
SPEAKER_00 (08:22):
Aaron Ross Powell The Fire is a protein called
Tau.
Amyloid plaques build up slowlyoutside the brain cells, setting
a toxic stage.
But tau proteins operate insidethe neurons.
SPEAKER_01 (08:32):
Inside the cell.
So how does tau actually destroythe cell?
SPEAKER_00 (08:34):
Well, inside every neuron, there's a transport
system that looks like tinytrain tracks carrying nutrients
from the center of the cell downto the synapses.
SPEAKER_01 (08:42):
Okay, I'm picturing it.
SPEAKER_00 (08:43):
In a healthy brain, tau acts like the wooden
railroad ties, holding thetracks straight and stable.
But in Alzheimer's, the tauproteins become deformed.
They detach from the tracks andtangle together into clumps.
SPEAKER_01 (08:55):
So the railroad ties just rot away.
SPEAKER_00 (08:57):
The ties dissolve, the tracks collapse, and the
neuron literally starves todeath from the inside out.
SPEAKER_01 (09:03):
That sounds brutal.
SPEAKER_00 (09:04):
It is.
This tau pathology remains theabsolute strongest biological
correlate of clinicalimpairment.
Where the tau goes, brain celldeath follows.
SPEAKER_01 (09:13):
Aaron Powell And to measure this, the study used a
highly advanced PE tracer calleduh 18F MK6240, and they found a
wild variance in the tau burdenamong these real-world patients
getting licanomap.
SPEAKER_00 (09:25):
The variance was staggering.
They measured the spread of thefire using break stages.
SPEAKER_01 (09:29):
Aaron Powell Break stages.
SPEAKER_00 (09:30):
Yeah.
Break stage zero means virtuallyno tau tangles, while stage six
means the tangles have spreadout of the memory centers and
swept across the entire brain,causing massive widespread
destruction.
SPEAKER_01 (09:44):
Aaron Powell What totally blew my mind in the
editorial was the disconnectbetween those stages and the
patient's actual symptoms.
SPEAKER_00 (09:51):
Right.
The clinical presentation.
SPEAKER_01 (09:52):
Yeah.
You had patients who performedidentically on memory tests in
the clinic.
I mean, they were at the exactsame clinical stage of cognitive
decline, but their brains lookedcompletely different on the PET
scans.
SPEAKER_00 (10:03):
Aaron Powell It's incredible.
You can have someone withminimal Tao burden who shows
undeniable severe cognitiveimpairment.
Yeah.
On the flip side, you havepatients with highly advanced
tau pathology, break stage fiveor six, who are still
functioning quite well,categorized only with mild
cognitive impairment.
SPEAKER_01 (10:20):
That's wild.
SPEAKER_00 (10:21):
They have a raging fire in their brain, yet they
are still holding a conversationand paying their bills.
SPEAKER_01 (10:25):
How is that even possible?
If the tau is actively starvingthe cells to death, how can
someone with a massive fire bedoing fine while someone with a
tiny spark is losing theirmemory?
SPEAKER_00 (10:36):
It comes down to a concept called cognitive
reserve.
It's basically the brain'smechanical resilience.
Okay.
Some brains develop incrediblydense, redundant neural networks
over a lifetime.
If a tau tangle destroys onepathway, a highly resilient
brain will just route theelectrical signal around the
damage, like a GPS finding adetour when a highway is
(10:58):
blocked.
SPEAKER_01 (10:59):
So the person with high tau just have more detours
built into their brain.
SPEAKER_00 (11:02):
Exactly.
They can sustain massivestructural damage before the
clinical symptoms appear simplybecause their brain keeps
improvising workarounds.
SPEAKER_01 (11:09):
That's amazing.
SPEAKER_00 (11:10):
And the person with low tau but severe symptoms
likely lacks those redundantpathways, or they have other
copathologies like the vascularearthquake damage we talked
about that have alreadydestroyed their detours.
SPEAKER_01 (11:22):
Aaron Powell So how does knowing a patient's tau
level change the decision toprescribe an amyloid drug if
you're just clearing out theamyloid plaques?
Why does the internal tau firematter?
SPEAKER_00 (11:33):
It matters heavily for setting realistic
expectations for the patient'sfuture.
How so?
If a patient comes in withextremely high tau levels, break
stage five or six, the cellularfire is already raging out of
control.
Removing the amyloid matches atthat late stage might not slow
down the clinical decline in ameaningful way.
SPEAKER_01 (11:51):
Ah, I see.
SPEAKER_00 (11:52):
The runaway train has already left the station.
SPEAKER_01 (11:54):
The structural damage is already done.
SPEAKER_00 (11:56):
Exactly.
But if patient has a very lowtau, they might be the ideal
candidate.
You remove the amyloid matchesbefore the widespread internal
fire ever really ignites,potentially offering genuine
long-term disease modification.
SPEAKER_01 (12:10):
Aaron Powell That reframes the entire
conversation.
You aren't just telling apatient, you know, take this
drug and you'll get better.
You're assessing their specificcellular fire to see if a
specific hose will actually putit out.
SPEAKER_00 (12:20):
Aaron Powell Which brings us to the broader ATNIVS
framework, the editorialchampions.
We've covered the A for amyloidand the T for tau.
Right.
But the framework demands welook at the hidden amplifiers of
the disease.
Neurodegeneration, which is theN inflammation, the I, vascular
pathology, the V, and alphasynucline, the S.
SPEAKER_01 (12:40):
Okay, let's look at those hidden amplifiers.
How are we measuring the N, theneurodegeneration?
SPEAKER_00 (12:46):
The study utilized plasma markers, basically
advanced blood tests.
For neurodegeneration, theymeasured plasma NFL or
neurofilament light chain.
SPEAKER_01 (12:55):
What are neurofilaments?
SPEAKER_00 (12:56):
They're the structural scaffolding proteins
that give a neuron its physicalshape.
When a brain cell finally diesand bursts open, that
scaffolding shatters and spillsout into the surrounding fluid,
eventually making its way intothe bloodstream.
So measuring high levels of NFLin the blood gives you a
real-time metric of active,ongoing brain cell death.
(13:17):
It's like seeing structuraldebris floating in the water
after a shipwreck.
SPEAKER_01 (13:21):
That is a dark image, but it makes perfect
sense.
And what about the eye forinflammation?
SPEAKER_00 (13:26):
For inflammation, they measured GFE, a protein
released by astrocytes.
Astrocytes are essentially themaintenance and immune crew of
the brain.
SPEAKER_01 (13:34):
The cleanup crew.
SPEAKER_00 (13:35):
Yeah.
When they detect damage likeamyloid plaques or dying cells,
they activate and try to clearthe debris.
But in neurodegenerativedisease, they often become
hyperactive, leading to chronic,toxic brain inflammation.
High GFA means the brain'simmune system is stuck in
overdrive.
SPEAKER_01 (13:52):
And we already covered the V, the vascular
pathology causing thosemicroscopic blood vessel
blockages.
So why are these three, thedying cells, the chronic
inflammation, and the vasculardamage, so critical when a
doctor is considering ananti-amyloid therapy?
SPEAKER_00 (14:06):
The most urgent reason is safety, specifically
the risk of a severe side effectcalled ARIA.
SPEAKER_01 (14:12):
ARI, amyloid-related imaging abnormalities.
This is the major safety warningon drugs like lacanimab,
involving brain swelling andmicrohemorrhages.
SPEAKER_00 (14:21):
Right.
To understand why ARIA happens,you have to look at how the drug
works mechanically.
These drugs are monoclonalantibodies designed to
forcefully strip amyloid out ofthe brain.
Okay.
But amyloid doesn't just sit inisolated plaques, it also embeds
itself deeply into the walls ofthe brain's blood vessels, a
condition called cerebralamyloid angiopathy.
SPEAKER_01 (14:39):
So the drug is literally attacking the amyloid
inside the blood vessel walls.
SPEAKER_00 (14:44):
Yes.
It triggers the brain's immunecells to attack and clear that
embedded amyloid.
If you do this in a patientwhose blood vessels are already
fragile and thickened fromvascular disease and surrounded
by hyperactive angry astrocytescausing inflammation, the
cleanup process is incrediblydestructive.
SPEAKER_01 (15:01):
That sounds dangerous.
SPEAKER_00 (15:02):
It is.
As the amyloid is stripped away,the compromised vessel walls
become porous, they leak fluid,causing brain swelling, or they
rupture entirely, causingbleeding.
SPEAKER_01 (15:12):
So if a doctor only looks at the binary amyloid
wristband and ignores theinflammation and vascular
damage, they might prescribe adrug to a patient whose blood
vessels literally cannot survivethe structural stress of the
cleanup.
SPEAKER_00 (15:25):
Exactly.
It's a profound safety risk thatis completely invisible if you
only focus on the amyloid.
SPEAKER_01 (15:30):
That is terrifying.
But there's one more letter inthis framework that caught me
completely off guard.
SPEAKER_00 (15:35):
The S.
SPEAKER_01 (15:36):
The S at the very end.
Alpha Sinucline.
SPEAKER_00 (15:39):
That finding is arguably the most provocative
paradigm shift in the entireeditorial.
SPEAKER_01 (15:44):
Because alpha synucline is a totally different
protein.
It's a one that misfolds andclumps together to form Lewy
bodies, which are the hallmarkof Parkinson's disease and Lewy
body dementia.
It has completely differentmechanisms than amyloid or tau.
SPEAKER_00 (15:58):
It does.
It attacks different regions ofthe brain and causes a very
different cascade of cellularfailure.
SPEAKER_01 (16:03):
Yet the study ran tests on these real-world
patients, people diagnosed withAlzheimer's disease who are
receiving an Alzheimer's drug,and found that roughly 25% of
them tested positive foralpha-sinuclein in their spinal
fluid.
A quarter of the patients.
SPEAKER_00 (16:16):
And many of them showed minimal, if any, clinical
signs of Lewy body disease.
Clinically, they just look likethey had Alzheimer's.
SPEAKER_01 (16:24):
How do the researchers even find it if
there were no symptoms?
SPEAKER_00 (16:27):
They used a revolutionary new tool called a
seed amplification assay, orSAA.
SPEAKER_01 (16:32):
How does an SAA actually work?
Like how do you find amicroscopic trace of a different
disease hidden in the spinalfluid?
SPEAKER_00 (16:39):
It's an ingenious piece of molecular engineering.
Alpha synucleane causes damageby misfolding and then
corrupting the healthy proteinsaround it, forcing them to
misfold too.
SPEAKER_01 (16:49):
Like a domino effect.
SPEAKER_00 (16:50):
Right.
The SAA exploits this behavior.
Researchers take a tiny sampleof the patient's spinal fluid
and place it in a tube filledwith perfectly healthy synthetic
alpha cytocline.
SPEAKER_01 (17:02):
So they mix the patient's fluid with normal
proteins.
SPEAKER_00 (17:04):
Then they shake it.
If the patient has even amicroscopic trace of the
misfolded seed in their fluid,it will start corrupting the
healthy synthetic proteins inthe tube, triggering a rapid
chain reaction.
SPEAKER_01 (17:16):
It's like dropping a single zombie into a crowded
room to see if an outbreakstarts.
SPEAKER_00 (17:21):
That is exactly the mechanism.
Within hours, the misfoldedproteins multiply until the
machine can easily detect them.
Wow.
And using this tool, wediscovered that 25% of these
Alzheimer's patients areactively harboring a second,
completely distinctneurodegenerative disease.
SPEAKER_01 (17:37):
So a quarter of these people have two separate
brain-destroying fires burningat the same time.
SPEAKER_00 (17:41):
If we connect this to the bigger picture, we call
it coproteinopathy.
The biology does not care aboutour neat diagnostic boxes.
SPEAKER_01 (17:48):
Obviously not.
SPEAKER_00 (17:49):
And having senuclein copathology drastically alters a
patient's prognosis.
The two diseases interact,accelerating the overall
cognitive decline.
And crucially, we currently havevery little data on how a brain
dealing with hidden alphasnuclein responds to an
anti-amyloid therapy.
SPEAKER_01 (18:07):
Because if you have a whole second army of proteins
destroying your neurons, justputting away the amyloid matches
might not even slow the declinedown.
SPEAKER_00 (18:14):
Right.
The clinical benefit might beentirely masked by the
progression of the hidden Lewybody pathology.
SPEAKER_01 (18:20):
So what does this all mean?
Zooming out from all thespecific proteins and
mechanisms, the core takeawayfor you listening is this
Alzheimer's disease is not asingle monolith.
SPEAKER_00 (18:30):
No, it's an umbrella term for a highly individualized
biological event.
SPEAKER_01 (18:34):
Anti-amyloid therapies are remarkable
breakthroughs, but they do notoperate in a vacuum.
The effects of removing amyloidunfold against an incredibly
complex backdrop of internal taufires, dying structural
scaffolding, vascular rust,brain inflammation, and
completely hiddenco-conspirators like
alpha-sinucline.
SPEAKER_00 (18:52):
The ATNIVS profile provides the multidimensional
map required for true precisionmedicine.
It allows a physician to look attwo patients who both have early
Alzheimer's and understand whythey have entirely different
trajectories, entirely differentside effect risks, and require
completely different care plans.
SPEAKER_01 (19:10):
We started this conversation talking about the
comforting simplicity of anx-ray, a clean binary problem
with a clean binary fix.
But the human brain is more likea massive, intricate orchestra.
SPEAKER_00 (19:23):
A very fragile orchestra.
SPEAKER_01 (19:24):
And if 25% of these patients have hidden alpha
synucline and others have heavyvascular damage or raging towel
fires, it means the stringsection is out of tune, the
brass is playing the wrong song,and the percussion is completely
missing.
Clearing out the amyloid is likefixing a single broken violin
string.
It's a start.
But you can't fix one string andexpect the symphony to sound
(19:46):
perfect.
It leaves you wondering ifyou're putting out one fire in a
burning house, what does thefuture of combination therapies
really look like?
SPEAKER_00 (19:54):
That's the only way forward.
SPEAKER_01 (19:55):
Imagine a bespoke personalized cocktail of
therapies tailored to targetyour exact biological signature.
We have to trade the comfort ofthe simple X ray for the power
of a multi dimensional map.
And while those diagnosticwaters might look murky right
now, mapping out every singleinstrument in that orchestra is
exactly what will help usfinally navigate them.
Popular Podcasts
Hey Jonas!
Hey Jonas! The official Jonas Brothers podcast. Hosted by Kevin, Joe, and Nick Jonas. It’s the Jonas Brothers you know... musicians, actors, and well, yes, brothers. Now, they’re sharing another side of themselves in the playful, intimate, and irreverent way only they can. Spend time with the Jonas Brothers here and stay a little bit longer for deep conversations like never before.
Crime Junkie
Does hearing about a true crime case always leave you scouring the internet for the truth behind the story? Dive into your next mystery with Crime Junkie. Every Monday, join your host Ashley Flowers as she unravels all the details of infamous and underreported true crime cases with her best friend Brit Prawat. From cold cases to missing persons and heroes in our community who seek justice, Crime Junkie is your destination for theories and stories you won’t hear anywhere else. Whether you're a seasoned true crime enthusiast or new to the genre, you'll find yourself on the edge of your seat awaiting a new episode every Monday. If you can never get enough true crime... Congratulations, you’ve found your people. Follow to join a community of Crime Junkies! Crime Junkie is presented by Audiochuck Media Company.
Betrayal Weekly
Betrayal Weekly is back for a new season. Every Thursday, Betrayal Weekly shares first-hand accounts of broken trust, shocking deceptions, and the trail of destruction they leave behind. Hosted by Andrea Gunning, this weekly ongoing series digs into real-life stories of betrayal and the aftermath. From stories of double lives to dark discoveries, these are cautionary tales and accounts of resilience against all odds. From the producers of the critically acclaimed Betrayal series, Betrayal Weekly drops new episodes every Thursday. If you would like to share your story, you can reach out to the Betrayal Team by emailing them at betrayalpod@gmail.com and follow us on Instagram at @betrayalpod and @glasspodcasts. Please join our Substack for additional exclusive content, curated book recommendations, and community discussions. Sign up FREE by clicking this link Beyond Betrayal Substack. Join our community dedicated to truth, resilience, and healing. Your voice matters! Be a part of our Betrayal journey on Substack.